Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study (SHARP): a 5-Week Double-blind, Placebo-controlled, Randomized, Crossover, Multicenter Study of Solriamfetol in Improving Cognitive Function in Participants With Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Plus Impaired Cognitive Function
Latest Information Update: 30 May 2024
At a glance
- Drugs Solriamfetol (Primary)
- Indications Hypersomnia
- Focus Therapeutic Use
- Acronyms SHARP
- Sponsors Axsome Therapeutics; Jazz Pharmaceuticals Inc
- 29 May 2024 According to an Axsome Therapeutics media release, data from the study will be presented at at SLEEP 2024, the 38th annual meeting of the American Academy of Sleep Medicine (AASM) and the Sleep Research Society (SRS), being held June 1-5, 2024, in Houston, Texas.
- 18 Apr 2024 Results assessing whether solriamfetol, a dopamine-norepinephrine reuptake inhibitor (DNRI) approved to improve wakefulness in adults with obstructive sleep apnea presented at the 76th Annual Meeting of the American Academy of Neurology 2024
- 07 Dec 2023 According to an Axsome Therapeutics media release, Dr. Bogan will provide an overview of this study at the virtual investor event and conference call.